TY - JOUR
T1 - Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
AU - Sciandra, Mariangela
AU - Borriello, Giovanna
AU - Gajofatto, Alberto
AU - Grossi, Paola
AU - Cortese, Antonio
AU - Bisecco, Alvino
AU - Ferrazzano, Gina
AU - Lucchini, Matteo
AU - Carotenuto, Antonio
AU - Chisari, Clara Grazia
AU - Valentino, Paola
AU - Ferrò, Maria Teresa
AU - Curti, Erica
AU - Gallo, Antonio
AU - Signoriello, Elisabetta
AU - Gobbin, Francesca
AU - Zanghì, Aurora
AU - Sparaco, Maddalena
AU - Bresciamorra, Vincenzo
AU - Tsantes, Elena
AU - Abbadessa, Gian Marco
AU - Lanzillo, Roberta
AU - Siena, Ernesto
AU - D’Amico, Emanuele
AU - Giugno, Alessia
AU - D’Amico, Emanuele
AU - Giugno, Alessia
AU - D’Amico, Emanuele
AU - Buccafusca, Maria
AU - Lus, Giacomo
AU - Bonavita, Simona
AU - Mirabella, Massimiliano
AU - Granella, Franco
AU - Grimaldi, Luigi Maria Edoardo
AU - Patti, Francesco
AU - Callari, Graziella
PY - 2020
Y1 - 2020
N2 - The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed the therapeutic landscape and algorithms of RRMS treatment (1). In Europe, dimethyl fumarate (DMF) and teriflunomide (TRF) are approved as first-line agents and are often used as the initial therapeutic choice (2, 3). Pivotal trials showed the efficacy of both DMTs on controlling clinical relapses, disability accrual and magnetic resonance imaging (MRI) activity (4-8). Both DMTs had overall good tolerability. There have been no head-to-head randomized trials to compare these two DMTs; however, several real-world evidence (RWE) studies have compared DMF and TRF and provided useful information to guide the selection of either drug for MS patients (9, 10). Although different statistical methods were used, both drugs demonstrated an ability to control disease activity (11-13). In some RWE studies, patients on DMF had a lower relapse rate and a higher relapse-free survival time (11, 12). In this registry-based nationwide cohort Cox-model study, we compared the clinical and radiological activity between patients treated with DMF or TRF.
AB - The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed the therapeutic landscape and algorithms of RRMS treatment (1). In Europe, dimethyl fumarate (DMF) and teriflunomide (TRF) are approved as first-line agents and are often used as the initial therapeutic choice (2, 3). Pivotal trials showed the efficacy of both DMTs on controlling clinical relapses, disability accrual and magnetic resonance imaging (MRI) activity (4-8). Both DMTs had overall good tolerability. There have been no head-to-head randomized trials to compare these two DMTs; however, several real-world evidence (RWE) studies have compared DMF and TRF and provided useful information to guide the selection of either drug for MS patients (9, 10). Although different statistical methods were used, both drugs demonstrated an ability to control disease activity (11-13). In some RWE studies, patients on DMF had a lower relapse rate and a higher relapse-free survival time (11, 12). In this registry-based nationwide cohort Cox-model study, we compared the clinical and radiological activity between patients treated with DMF or TRF.
UR - http://hdl.handle.net/10447/422711
M3 - Article
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
ER -